Nonchemotherapy-based approaches, including PI3K inhibitors and a more widespread use of allogeneic stem cell transplant, are being explored as treatments for patients with follicular lymphoma, according to Michael L. Grossbard, MD, who added that CAR T-cell therapy is also being evaluated.
“As time has gone by, we have tried to move more toward nonchemotherapy brute force approaches to managing follicular lymphoma,” said Grossbard, a professor in the Department of Medicine, chief of the Hematology and Medical Oncology Inpatient Service at Tisch Hospital, NYU Langone Health’s Perlmutter Cancer Center.
Grossbard, who is also section chief of Hematology at NYU Langone Health’s Perlmutter Cancer Center, spoke with OncLive®, CancerNetwork®’s sister publication, about these recent developments in the field of follicular lymphoma.
“Follicular lymphoma is easy to get…
